Compare ARK Space & Defense Innovation ETF (ARKX) vs HCA Health Inc (HCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Space & Defense Innovation ETF vs HCA Health Inc — how do they compare? ARK Space & Defense Innovation ETF trades at $31.86, while HCA Health Inc trades at $407.38 (market cap $90.20B). The key difference: HCA Health Inc pays a 0.77% dividend while ARK Space & Defense Innovation ETF pays none, and ARK Space & Defense Innovation ETF is trading nearer its 52-week high, HCA Health Inc nearer its low. Which is the better fit depends on your goals.
| ARKX | HCA | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $37.74 | $545.13 |
52-Week Low | $24.97 | $334.32 |
Market Cap | — | $90.20B |
Enterprise Value | — | $139.10B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Space Exploration & Innovation ETF (ARKX) trades at $32.05, down 0.82% today amid bearish technical signals. The ETF shows neutral oscillator readings but bearish moving averages, with key support at $32 and resistance at $33. Recent news highlights ARKX as a popular alternative to direct SpaceX investment, with the space economy reaching $500 billion in backlog according to 24/7 Wall Street (2026-07-06).
ARKX offers diversified exposure to the growing space sector without single-stock IPO risk. The ETF's higher volatility and expense ratio compared to traditional aerospace ETFs present both growth potential and increased risk. SpaceX's 8.31% weighting provides significant upside exposure but also concentration risk in a high-valuation name.
HCA Healthcare trades at $406.59, down 0.59% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $7.37. Revenue growth is robust, reaching $75.60 billion in 2025, while valuation metrics like a P/E of 14.01 and EV/EBITDA of 8.88 suggest relative attractiveness. Recent news highlights capacity expansion and gene therapy advancements.
The outlook for HCA remains positive, supported by earnings momentum and strategic investments, but risks include high debt levels and regulatory pressures. Analyst consensus is bullish with a $486.10 price target, indicating ~20% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Space & Defense Innovation ETF
ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.
Read more on ARKX →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
